Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database

Boonmuang P 1 , Nathisuwan S 2 , Chaiyakunapruk N 3 , Suwankesawong W 4 , Pokhagul P 4 , Teerawattanapong N 5 Show all authors , Supsongserm P 6

Affiliations 

  • 1 Faculty of Pharmacy, Prince of Songkla University, Songkla, Thailand
  • 2 Faculty of Pharmacy, Mahidol University, 447 Sri-ayutthaya Road, Rajthewi, Bangkok, 10400, Thailand. surakit.nat@mahidol.ac.th
  • 3 Discipline of Pharmacy, Monash University Sunway Campus, Selangor, Malaysia; School of Population Health, University of Queensland, Brisbane, QLD, Australia; School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA; Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
  • 4 Health Product Vigilance Center, Food and Drug Administration, Ministry of Public Health, Nonthaburi, Thailand
  • 5 Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
  • 6 Faculty of Pharmacy, Mahidol University, 447 Sri-ayutthaya Road, Rajthewi, Bangkok, 10400, Thailand
Drug Saf, 2013 Sep;36(9):779-87.
PMID: 23615756 DOI: 10.1007/s40264-013-0055-5

Abstract

HMG-CoA reductase inhibitors [statins], a widely prescribed cholesterol-lowering therapy, are associated with muscle-related adverse events. While characteristics of such events are well documented in Western countries, little data exists for the Thai population.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications